Skip to main content
. 2024 Apr 12;72:103157. doi: 10.1016/j.redox.2024.103157

Fig. 8.

Fig. 8

Pharmacological inhibition of METTL3 protects against DOX-induced ferroptosis and cardiotoxicity. (A) Schematic timeline of DOX and STM2457 treatments. (B) Representative M-mode echocardiographic, Masson trichrome staining and HE staining images. (C) and (D) Statistical analysis of left ventricular ejection fraction (LVEF) and fractional shortening (LVFS). (E) Quantitative analysis of cardiac interstitial fibrosis. (F) Plasma cTnT levels in mice treated with DOX or STM2457. (G) and (H) Quantitative analysis of cardiomyocyte areas and heart weight (HW)-to-tibial length (TL) ratio in mice treated with DOX or STM2457. (I) Representative immunoblotting of 4-HNE, and quantitative analysis of 4-HNE levels in heart tissues of mice with indicated treatments. (J) Malondialdehyde (MDA) levels in heart tissues. (K) GSH/GSSG levels in heart tissues. (K) Total, ferrous, and ferric iron levels in mouse heart tissues with indicated treatments. Mean ± SEM. n = 6 per group. P values were determined by one-way ANOVA with Tukey's post-hoc test (C, D, E, F, and G-L). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.